GlassScriptPhysician profile
Manolito Cadacio
NPI 1447440680
$2,716.18
in general payments reported to CMS, 2019-2025
23 companies · $965 in 2025
The $965 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2021: $67.21 · 2022: $14.67 · 2023: $278 · 2024: $1,191 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,433.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.81 | 2021-2025 | Ozempic, Rybelsus, Rivfloza |
| Amgen INC. | $386.58 | 2019-2025 | Evenity, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $305.24 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $246.48 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $239.34 | 2019-2025 | |
| Abbvie INC. | $224.44 | 2021-2025 | Synthroid, Teflaro, Dalvance |
| Phathom Pharmaceuticals, INC. | $215.28 | 2024-2025 | Voquezna |
| Abbott Laboratories | $127.60 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $73.63 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $66.52 | 2025 | |
| Exact Sciences Corporation | $61.99 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $59.48 | 2019-2024 | Injectafer |
| Glaxosmithkline, LLC. | $30.66 | 2019-2025 | Shingrix |
| Teva Pharmaceuticals USA, INC. | $29.52 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $28.54 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.83 | 2019 | |
| Lundbeck LLC | $17.71 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $14.42 | 2025 | Uptravi, Opsumit |
| Paratek Pharmaceuticals, INC. | $14.22 | 2024 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $14.18 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $13.51 | 2019 | |
| Amarin Pharma, INC. | $12.20 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manolito Cadacio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.